

F. No: BD/VET.CELL/ 04-2017  
Directorate of General of Health Services  
Central Drugs Standard Control Organization  
FDA Bhawan, Kotla Road, New Delhi  
(O/o DCG (I))

OFFICE MEMORANDUM

30 MAR 2017


**Subject: Strict regulatory control over manufacture, sale and distribution of oxytocin and to curb its misuse -reg.**

The Secretary, Health and Family Welfare, Ministry of Health and Family Welfare took a meeting on 14.03.2017 to take stock of situation relating to restricting and regulating manufacturing of oxytocin and to permit its manufacturing in PSU in compliance to the judgment of the High Court of Himachal Pradesh.

It was decided in the meeting that a mechanism should be created in CDSCO to receive complaints regarding illegal production of oxytocin and its misuse in the country.

All the Zonal / Sub- Zonal / Port offices of CDSCO are hereby directed to create a mechanism of receiving complaints regarding illegal production / import of oxytocin and its misuse in the country through E-mail or other means including a Complaint Box in their respective offices as well as a system to address such complaints.

A monthly report in this regard should be forwarded to CDSCO (HQ), (with attention to Mr. S. Dey, DDC (I) to ensure that the drug is manufactured in the country for human and animals in compliance to the regulatory provisions of the Drugs and Cosmetics Act, 1940 and Rules 1945 made thereunder and its misuse is curbed.

  
(Dr. G. N. Singh)  
Drugs Controller General (India)

To

All Zonal/ Sub-Zonal / Port offices of CDSCO